HCP1306 clinical trials
Also written HCP1306.
How each study uses HCP1306 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HCP1306 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HCP1306
- 5
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Amlodipine (2) · HGP0608 (2) · RLD2302 (1) · RLD2102 (1) · HGP0816 (1) · HGP1404 (1) · HIP2503 (1)
Studies
Open first, then newest update. How each study uses HCP1306 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy VolunteersNot yet recruitingPhase 1Hanmi Pharmaceutical Company LimitedNCT07297693Written as HCP1306
- A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy VolunteersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT06518122Written as HCP1306
- A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.CompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT04322266Written as HCP1306
- A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.CompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT04081844Written as HCP1306
- Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male VolunteersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT02941848Written as HCP1306